$XRTX.V

XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange

XORTX Therapeutics (XRTX.V, XRTX) on Monday provided a corporate update and announced the appointment of Mika Grasso as co-chief executive officer, responsible for finance and public markets.This comes after the company had said after markets closed on Friday that it has elected to voluntarily delist its common shares from the TSX Venture Exchange. It will provide additional information on timing for the completion of the delisting of its common shares in a separate press release."This decision was taken following a comprehensive evaluation, the company determined that maintaining a dual listing on the TSXV does not justify the associated costs and administrative requirements and presents challenges due to the different regulatory environments," the company said. "It is envisioned that the voluntary delisting will eliminate duplicative exchange fees, reduce legal and accounting expenses, optimize company financing initiatives and minimize regulatory complexity, and enable greater management focus on the advancement of the XRx-026 program for the treatment of gout for long-term shareholder value creation."

XORTX Therapeutics Providing Corporate Update and Appoints Mika Grasso as Co-CEO

XORTX Therapeutics Raises US$5 Million Via Public Offering

XORTX Therapeutics (XRTX.V, XRTX) closed its previously announced public offering of 2.7-million common shares or common shares equivalents in lieu thereof at US$1.88 apiece, it said Tuesday.The company, as part of the offering, had entered into definitive securities purchase agreements with purchasers to which the company issued 183,577 common shares and 2.5-million pre-funded warrants. Each pre-funded warrant will entitle the holder to buy a share for $0.0001 per share.Proceeds were US$5 million, before deducting placement agent fees and other offering expenses payable by the company, it said. It intends to use the net proceeds for working capital and general corporate needs.U.S.-listed shares of the company were last seen down 0.4% at US$2.59 in pre-market trading.

XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9%

XORTX Therapeutics (XRTX.V, XRTX) on Thursday said it will raise US$5 million in a public offering of share and pre-funded warrants.The company said it will offer up to 2.6-million share or prefunded warrants priced at US$1.88.The pre-funded warrants have an exercise price of US$0.0001 per share, will be immediately exercisable, and will terminate once exercised in full, said the company.The offering is expected to close on or about May 15.The company's shares were last seen down C$0.27 to C$2.76 on the TSX Venture Exchange.Price: $2.76, Change: $-0.27, Percent Change: -8.91%

XORTX Therapeutics Says Met Nasdaq Continued Listing Requirements